Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 09/29 10:00:00 pm
165.45 USD   -2.51%
01:35a AMGEN : Arrowhead Pharmaceuticals inks drug development deal with Am..
09/29DJARROWHEAD PHARM : Amgen, Arrowhead Pharma Agree to Cardiovascular Co..
09/29 AMGEN : And Arrowhead Pharmaceuticals Announce Two Cardiovascular Co..
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 04:55am CEST

THOUSAND OAKS, Calif., April 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away.

Recruited by Bill Bowes, one of Amgen's founders, Rathmann possessed the kind of passion and charisma that helped build the company and attract world-class scientific talent. Regarded as one of the founding fathers of biotechnology, George had the vision to see how biotechnology could transform the practice of medicine with the mix of business and science to bring that vision to life. One of Rathmann's chief accomplishments was finding the funds Amgen needed during its start-up years. Nicknamed the "Golden Throat" by friends who admired his persuasiveness, he secured venture capital, built revenue streams through partnerships, and guided Amgen through its first public offerings.

"George Rathmann was a biotechnology giant and we were privileged to have him as our first CEO. George's vision and values are as alive today at Amgen as they were when he led the Company," said Kevin Sharer, Chairman and CEO of Amgen. "Bob Bradway, our next CEO, and I both share George's commitment to patients and conviction that being science-based is the best foundation for innovation in biotechnology."

Through the years, Amgen has continued to recognize the significant impact Rathmann made on the Company. In 2004, a full-size sculpture of Rathmann was dedicated on Amgen's campus in recognition of his leadership. In 2005, Amgen created the annual George B. Rathmann Award, the company's highest honor, to recognize staff members who exemplify Amgen's standards of excellence to advance Amgen's mission to serve patients.

Rathmann was recognized as BIO's CEO of the year in 1987 and 1988. Upon leaving Amgen, Rathmann became CEO and chairman of Seattle-based biotech ICOS Corporation (later acquired by Eli Lilly). He later served as CEO and chairman of genomics company Hyseq, Inc.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN, INC.
01:35a AMGEN : Arrowhead Pharmaceuticals inks drug development deal with Amgen worth up..
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/29 AMGEN : And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
09/28 AMGEN : Announces Erenumab Significantly Reduces Monthly Migraine Days In Patien..
09/28 AMGEN : Assigned Patent
09/27 NASDAQ 100 MOVERS : Gild, nclh
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/27 AMGEN : Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION ..
09/26 AMGEN : Opens Nomination Process For LabCentral Residency
09/26 AMGEN : And UCB Announce U.S. FDA Acceptance Of Biologics License Application Fo..
More news
Sector news : Bio Therapeutic Drugs
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
09/13DJGILEAD SCIENCES : Scientists Honored for Hep C Research
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/29 Shire Cedes Biosimilar Field
09/29 NASDAQ : From Laggard To Leader
09/29 Arrowhead Pharma inks two agreements with Amgen for RNAi candidates in cardio..
09/28 Amgen's erenumab (AMG 334) successful in late-stage study in migraine prevent..
09/28 BIOTECH FORUM DAILY DIGEST : Notable Trial Failures; NASH Continues To Be Tough ..